Search - tctmd.com

Displaying 761 - 780 of 1464

Sort: Relevancy | Date

News Daily News

FDA Allows Claim About Oleic Acid’s Possible Heart Benefits on Labeling

Todd Neale

November 19, 2018

News Conference News AHA 2018

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Yael L. Maxwell

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Conference News AHA 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

Shelley Wood

November 10, 2018

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

Michael O'Riordan

November 06, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Daily News

European Guidelines Represent First Intersocietal Position on Percutaneous PFO Closure

Yael L. Maxwell

November 01, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

Lingering Signs of Inflammation Post-PCI Signal More Death, MI at 1 Year

Caitlin E. Cox

October 31, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2018

Shelley Wood

October 31, 2018

News Daily News

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

Yael L. Maxwell

October 30, 2018

News Daily News

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Shelley Wood

October 29, 2018

News Daily News

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Michael O'Riordan

October 25, 2018

News Daily News

Patients With Schizophrenia Reap Gains From CV Meds After MI

Todd Neale

October 24, 2018

Advertisement

FDA Allows Claim About Oleic Acid’s Possible Heart Benefits on Labeling

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

European Guidelines Represent First Intersocietal Position on Percutaneous PFO Closure

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Lingering Signs of Inflammation Post-PCI Signal More Death, MI at 1 Year

TCTMD’s Top 10 Most Popular Stories for October 2018

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Patients With Schizophrenia Reap Gains From CV Meds After MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content